Research ArticleAccepted Article
Open Access
Women with Psoriatic Arthritis Experience Higher Disease Burden than Men: Findings from a Real-World Survey in the USA and Europe
Laure Gossec, Jessica A. Walsh, Kaleb Michaud, Steve Peterson, Elizabeth A. Holdsworth, Chetan S. Karyekar, Nicola Booth, Soumya D. Chakravarty and Alexis Ogdie
The Journal of Rheumatology August 2022, jrheum.220154; DOI: https://doi.org/10.3899/jrheum.220154
Laure Gossec
Sources of support: This study was funded by Janssen Research & Development, LLC. Data collection was undertaken by Adelphi Real World as part of an independent survey, entitled the Adelphi Psoriatic Arthritis Disease Specific Programme™. Janssen Research & Development, LLC did not influence the original survey through either contribution to the design of questionnaires or data collection. All data that support the findings of this study are the intellectual property of Adelphi Real World. All requests for access should be addressed directly to Nicola Booth at nicola.booth@adelphigroup.com. Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France; Pitié-Salpêtrière Hospital, AP-HP. Sorbonne Université, Rheumatology department, Paris, France; University of Utah Health and Salt Lake City Veterans Affairs Medical Center, Salt Lake City, UT, USA; University of Nebraska Medical Center, Omaha, NE, USA; Forward Databank, Wichita, KA, USA; Janssen Global Services, LLC, Horsham, PA, USA; Adelphi Real World, Bollington, UK; Janssen Research & Development, Spring House, PA, USA; Janssen Scientific Affairs, LLC, USA; Drexel University College of Medicine, Philadelphia, PA, USA; 11Perelman School of Medicine, Penn Medicine, Philadelphia, PA, USA. Conflicts of interest: LG: Research grants: Amgen, Galapagos, Janssen, Lilly, Pfizer, Sandoz, Sanofi; consulting fees: AbbVie, Amgen, BMS, Biogen, Celgene, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. JAW: Grants from AbbVie, Merck, Pfizer. Consulting for AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB, all unrelated to this work. KM: None disclosed. SP and CSK are employees and shareholders of Janssen Pharmaceuticals LLC. EAH and NB are employees of Adelphi Real World. SDC is an employee of Janssen Scientific Affairs, LLC and a shareholder in Johnson & Johnson, of which Janssen Scientific Affairs, LLC is a wholly-owned subsidiary. AO: Grant/research support from Amgen (to Forward), Novartis (to Penn) and Pfizer (to Penn) Inc. Consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Eli Lilly, Gilead, Janssen, Novartis, Pfizer Inc, and UCB. Address for correspondence: Pr. Laure Gossec Orcid ID: 0000-0002-4528-310X Hôpital Pitié-Salpétrière, Service de Rhumatologie, 47-83, boulevard de l'Hôpital - 75013 Paris, France laure.gossec@aphp.fr
Jessica A. Walsh
Sources of support: This study was funded by Janssen Research & Development, LLC. Data collection was undertaken by Adelphi Real World as part of an independent survey, entitled the Adelphi Psoriatic Arthritis Disease Specific Programme™. Janssen Research & Development, LLC did not influence the original survey through either contribution to the design of questionnaires or data collection. All data that support the findings of this study are the intellectual property of Adelphi Real World. All requests for access should be addressed directly to Nicola Booth at nicola.booth@adelphigroup.com. Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France; Pitié-Salpêtrière Hospital, AP-HP. Sorbonne Université, Rheumatology department, Paris, France; University of Utah Health and Salt Lake City Veterans Affairs Medical Center, Salt Lake City, UT, USA; University of Nebraska Medical Center, Omaha, NE, USA; Forward Databank, Wichita, KA, USA; Janssen Global Services, LLC, Horsham, PA, USA; Adelphi Real World, Bollington, UK; Janssen Research & Development, Spring House, PA, USA; Janssen Scientific Affairs, LLC, USA; Drexel University College of Medicine, Philadelphia, PA, USA; 11Perelman School of Medicine, Penn Medicine, Philadelphia, PA, USA. Conflicts of interest: LG: Research grants: Amgen, Galapagos, Janssen, Lilly, Pfizer, Sandoz, Sanofi; consulting fees: AbbVie, Amgen, BMS, Biogen, Celgene, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. JAW: Grants from AbbVie, Merck, Pfizer. Consulting for AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB, all unrelated to this work. KM: None disclosed. SP and CSK are employees and shareholders of Janssen Pharmaceuticals LLC. EAH and NB are employees of Adelphi Real World. SDC is an employee of Janssen Scientific Affairs, LLC and a shareholder in Johnson & Johnson, of which Janssen Scientific Affairs, LLC is a wholly-owned subsidiary. AO: Grant/research support from Amgen (to Forward), Novartis (to Penn) and Pfizer (to Penn) Inc. Consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Eli Lilly, Gilead, Janssen, Novartis, Pfizer Inc, and UCB. Address for correspondence: Pr. Laure Gossec Orcid ID: 0000-0002-4528-310X Hôpital Pitié-Salpétrière, Service de Rhumatologie, 47-83, boulevard de l'Hôpital - 75013 Paris, France laure.gossec@aphp.fr
Kaleb Michaud
Sources of support: This study was funded by Janssen Research & Development, LLC. Data collection was undertaken by Adelphi Real World as part of an independent survey, entitled the Adelphi Psoriatic Arthritis Disease Specific Programme™. Janssen Research & Development, LLC did not influence the original survey through either contribution to the design of questionnaires or data collection. All data that support the findings of this study are the intellectual property of Adelphi Real World. All requests for access should be addressed directly to Nicola Booth at nicola.booth@adelphigroup.com. Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France; Pitié-Salpêtrière Hospital, AP-HP. Sorbonne Université, Rheumatology department, Paris, France; University of Utah Health and Salt Lake City Veterans Affairs Medical Center, Salt Lake City, UT, USA; University of Nebraska Medical Center, Omaha, NE, USA; Forward Databank, Wichita, KA, USA; Janssen Global Services, LLC, Horsham, PA, USA; Adelphi Real World, Bollington, UK; Janssen Research & Development, Spring House, PA, USA; Janssen Scientific Affairs, LLC, USA; Drexel University College of Medicine, Philadelphia, PA, USA; 11Perelman School of Medicine, Penn Medicine, Philadelphia, PA, USA. Conflicts of interest: LG: Research grants: Amgen, Galapagos, Janssen, Lilly, Pfizer, Sandoz, Sanofi; consulting fees: AbbVie, Amgen, BMS, Biogen, Celgene, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. JAW: Grants from AbbVie, Merck, Pfizer. Consulting for AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB, all unrelated to this work. KM: None disclosed. SP and CSK are employees and shareholders of Janssen Pharmaceuticals LLC. EAH and NB are employees of Adelphi Real World. SDC is an employee of Janssen Scientific Affairs, LLC and a shareholder in Johnson & Johnson, of which Janssen Scientific Affairs, LLC is a wholly-owned subsidiary. AO: Grant/research support from Amgen (to Forward), Novartis (to Penn) and Pfizer (to Penn) Inc. Consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Eli Lilly, Gilead, Janssen, Novartis, Pfizer Inc, and UCB. Address for correspondence: Pr. Laure Gossec Orcid ID: 0000-0002-4528-310X Hôpital Pitié-Salpétrière, Service de Rhumatologie, 47-83, boulevard de l'Hôpital - 75013 Paris, France laure.gossec@aphp.fr
Steve Peterson
Sources of support: This study was funded by Janssen Research & Development, LLC. Data collection was undertaken by Adelphi Real World as part of an independent survey, entitled the Adelphi Psoriatic Arthritis Disease Specific Programme™. Janssen Research & Development, LLC did not influence the original survey through either contribution to the design of questionnaires or data collection. All data that support the findings of this study are the intellectual property of Adelphi Real World. All requests for access should be addressed directly to Nicola Booth at nicola.booth@adelphigroup.com. Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France; Pitié-Salpêtrière Hospital, AP-HP. Sorbonne Université, Rheumatology department, Paris, France; University of Utah Health and Salt Lake City Veterans Affairs Medical Center, Salt Lake City, UT, USA; University of Nebraska Medical Center, Omaha, NE, USA; Forward Databank, Wichita, KA, USA; Janssen Global Services, LLC, Horsham, PA, USA; Adelphi Real World, Bollington, UK; Janssen Research & Development, Spring House, PA, USA; Janssen Scientific Affairs, LLC, USA; Drexel University College of Medicine, Philadelphia, PA, USA; 11Perelman School of Medicine, Penn Medicine, Philadelphia, PA, USA. Conflicts of interest: LG: Research grants: Amgen, Galapagos, Janssen, Lilly, Pfizer, Sandoz, Sanofi; consulting fees: AbbVie, Amgen, BMS, Biogen, Celgene, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. JAW: Grants from AbbVie, Merck, Pfizer. Consulting for AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB, all unrelated to this work. KM: None disclosed. SP and CSK are employees and shareholders of Janssen Pharmaceuticals LLC. EAH and NB are employees of Adelphi Real World. SDC is an employee of Janssen Scientific Affairs, LLC and a shareholder in Johnson & Johnson, of which Janssen Scientific Affairs, LLC is a wholly-owned subsidiary. AO: Grant/research support from Amgen (to Forward), Novartis (to Penn) and Pfizer (to Penn) Inc. Consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Eli Lilly, Gilead, Janssen, Novartis, Pfizer Inc, and UCB. Address for correspondence: Pr. Laure Gossec Orcid ID: 0000-0002-4528-310X Hôpital Pitié-Salpétrière, Service de Rhumatologie, 47-83, boulevard de l'Hôpital - 75013 Paris, France laure.gossec@aphp.fr
Elizabeth A. Holdsworth
Sources of support: This study was funded by Janssen Research & Development, LLC. Data collection was undertaken by Adelphi Real World as part of an independent survey, entitled the Adelphi Psoriatic Arthritis Disease Specific Programme™. Janssen Research & Development, LLC did not influence the original survey through either contribution to the design of questionnaires or data collection. All data that support the findings of this study are the intellectual property of Adelphi Real World. All requests for access should be addressed directly to Nicola Booth at nicola.booth@adelphigroup.com. Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France; Pitié-Salpêtrière Hospital, AP-HP. Sorbonne Université, Rheumatology department, Paris, France; University of Utah Health and Salt Lake City Veterans Affairs Medical Center, Salt Lake City, UT, USA; University of Nebraska Medical Center, Omaha, NE, USA; Forward Databank, Wichita, KA, USA; Janssen Global Services, LLC, Horsham, PA, USA; Adelphi Real World, Bollington, UK; Janssen Research & Development, Spring House, PA, USA; Janssen Scientific Affairs, LLC, USA; Drexel University College of Medicine, Philadelphia, PA, USA; 11Perelman School of Medicine, Penn Medicine, Philadelphia, PA, USA. Conflicts of interest: LG: Research grants: Amgen, Galapagos, Janssen, Lilly, Pfizer, Sandoz, Sanofi; consulting fees: AbbVie, Amgen, BMS, Biogen, Celgene, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. JAW: Grants from AbbVie, Merck, Pfizer. Consulting for AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB, all unrelated to this work. KM: None disclosed. SP and CSK are employees and shareholders of Janssen Pharmaceuticals LLC. EAH and NB are employees of Adelphi Real World. SDC is an employee of Janssen Scientific Affairs, LLC and a shareholder in Johnson & Johnson, of which Janssen Scientific Affairs, LLC is a wholly-owned subsidiary. AO: Grant/research support from Amgen (to Forward), Novartis (to Penn) and Pfizer (to Penn) Inc. Consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Eli Lilly, Gilead, Janssen, Novartis, Pfizer Inc, and UCB. Address for correspondence: Pr. Laure Gossec Orcid ID: 0000-0002-4528-310X Hôpital Pitié-Salpétrière, Service de Rhumatologie, 47-83, boulevard de l'Hôpital - 75013 Paris, France laure.gossec@aphp.fr
Chetan S. Karyekar
Sources of support: This study was funded by Janssen Research & Development, LLC. Data collection was undertaken by Adelphi Real World as part of an independent survey, entitled the Adelphi Psoriatic Arthritis Disease Specific Programme™. Janssen Research & Development, LLC did not influence the original survey through either contribution to the design of questionnaires or data collection. All data that support the findings of this study are the intellectual property of Adelphi Real World. All requests for access should be addressed directly to Nicola Booth at nicola.booth@adelphigroup.com. Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France; Pitié-Salpêtrière Hospital, AP-HP. Sorbonne Université, Rheumatology department, Paris, France; University of Utah Health and Salt Lake City Veterans Affairs Medical Center, Salt Lake City, UT, USA; University of Nebraska Medical Center, Omaha, NE, USA; Forward Databank, Wichita, KA, USA; Janssen Global Services, LLC, Horsham, PA, USA; Adelphi Real World, Bollington, UK; Janssen Research & Development, Spring House, PA, USA; Janssen Scientific Affairs, LLC, USA; Drexel University College of Medicine, Philadelphia, PA, USA; 11Perelman School of Medicine, Penn Medicine, Philadelphia, PA, USA. Conflicts of interest: LG: Research grants: Amgen, Galapagos, Janssen, Lilly, Pfizer, Sandoz, Sanofi; consulting fees: AbbVie, Amgen, BMS, Biogen, Celgene, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. JAW: Grants from AbbVie, Merck, Pfizer. Consulting for AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB, all unrelated to this work. KM: None disclosed. SP and CSK are employees and shareholders of Janssen Pharmaceuticals LLC. EAH and NB are employees of Adelphi Real World. SDC is an employee of Janssen Scientific Affairs, LLC and a shareholder in Johnson & Johnson, of which Janssen Scientific Affairs, LLC is a wholly-owned subsidiary. AO: Grant/research support from Amgen (to Forward), Novartis (to Penn) and Pfizer (to Penn) Inc. Consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Eli Lilly, Gilead, Janssen, Novartis, Pfizer Inc, and UCB. Address for correspondence: Pr. Laure Gossec Orcid ID: 0000-0002-4528-310X Hôpital Pitié-Salpétrière, Service de Rhumatologie, 47-83, boulevard de l'Hôpital - 75013 Paris, France laure.gossec@aphp.fr
Nicola Booth
Sources of support: This study was funded by Janssen Research & Development, LLC. Data collection was undertaken by Adelphi Real World as part of an independent survey, entitled the Adelphi Psoriatic Arthritis Disease Specific Programme™. Janssen Research & Development, LLC did not influence the original survey through either contribution to the design of questionnaires or data collection. All data that support the findings of this study are the intellectual property of Adelphi Real World. All requests for access should be addressed directly to Nicola Booth at nicola.booth@adelphigroup.com. Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France; Pitié-Salpêtrière Hospital, AP-HP. Sorbonne Université, Rheumatology department, Paris, France; University of Utah Health and Salt Lake City Veterans Affairs Medical Center, Salt Lake City, UT, USA; University of Nebraska Medical Center, Omaha, NE, USA; Forward Databank, Wichita, KA, USA; Janssen Global Services, LLC, Horsham, PA, USA; Adelphi Real World, Bollington, UK; Janssen Research & Development, Spring House, PA, USA; Janssen Scientific Affairs, LLC, USA; Drexel University College of Medicine, Philadelphia, PA, USA; 11Perelman School of Medicine, Penn Medicine, Philadelphia, PA, USA. Conflicts of interest: LG: Research grants: Amgen, Galapagos, Janssen, Lilly, Pfizer, Sandoz, Sanofi; consulting fees: AbbVie, Amgen, BMS, Biogen, Celgene, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. JAW: Grants from AbbVie, Merck, Pfizer. Consulting for AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB, all unrelated to this work. KM: None disclosed. SP and CSK are employees and shareholders of Janssen Pharmaceuticals LLC. EAH and NB are employees of Adelphi Real World. SDC is an employee of Janssen Scientific Affairs, LLC and a shareholder in Johnson & Johnson, of which Janssen Scientific Affairs, LLC is a wholly-owned subsidiary. AO: Grant/research support from Amgen (to Forward), Novartis (to Penn) and Pfizer (to Penn) Inc. Consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Eli Lilly, Gilead, Janssen, Novartis, Pfizer Inc, and UCB. Address for correspondence: Pr. Laure Gossec Orcid ID: 0000-0002-4528-310X Hôpital Pitié-Salpétrière, Service de Rhumatologie, 47-83, boulevard de l'Hôpital - 75013 Paris, France laure.gossec@aphp.fr
Soumya D. Chakravarty
Sources of support: This study was funded by Janssen Research & Development, LLC. Data collection was undertaken by Adelphi Real World as part of an independent survey, entitled the Adelphi Psoriatic Arthritis Disease Specific Programme™. Janssen Research & Development, LLC did not influence the original survey through either contribution to the design of questionnaires or data collection. All data that support the findings of this study are the intellectual property of Adelphi Real World. All requests for access should be addressed directly to Nicola Booth at nicola.booth@adelphigroup.com. Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France; Pitié-Salpêtrière Hospital, AP-HP. Sorbonne Université, Rheumatology department, Paris, France; University of Utah Health and Salt Lake City Veterans Affairs Medical Center, Salt Lake City, UT, USA; University of Nebraska Medical Center, Omaha, NE, USA; Forward Databank, Wichita, KA, USA; Janssen Global Services, LLC, Horsham, PA, USA; Adelphi Real World, Bollington, UK; Janssen Research & Development, Spring House, PA, USA; Janssen Scientific Affairs, LLC, USA; Drexel University College of Medicine, Philadelphia, PA, USA; 11Perelman School of Medicine, Penn Medicine, Philadelphia, PA, USA. Conflicts of interest: LG: Research grants: Amgen, Galapagos, Janssen, Lilly, Pfizer, Sandoz, Sanofi; consulting fees: AbbVie, Amgen, BMS, Biogen, Celgene, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. JAW: Grants from AbbVie, Merck, Pfizer. Consulting for AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB, all unrelated to this work. KM: None disclosed. SP and CSK are employees and shareholders of Janssen Pharmaceuticals LLC. EAH and NB are employees of Adelphi Real World. SDC is an employee of Janssen Scientific Affairs, LLC and a shareholder in Johnson & Johnson, of which Janssen Scientific Affairs, LLC is a wholly-owned subsidiary. AO: Grant/research support from Amgen (to Forward), Novartis (to Penn) and Pfizer (to Penn) Inc. Consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Eli Lilly, Gilead, Janssen, Novartis, Pfizer Inc, and UCB. Address for correspondence: Pr. Laure Gossec Orcid ID: 0000-0002-4528-310X Hôpital Pitié-Salpétrière, Service de Rhumatologie, 47-83, boulevard de l'Hôpital - 75013 Paris, France laure.gossec@aphp.fr
Alexis Ogdie
Sources of support: This study was funded by Janssen Research & Development, LLC. Data collection was undertaken by Adelphi Real World as part of an independent survey, entitled the Adelphi Psoriatic Arthritis Disease Specific Programme™. Janssen Research & Development, LLC did not influence the original survey through either contribution to the design of questionnaires or data collection. All data that support the findings of this study are the intellectual property of Adelphi Real World. All requests for access should be addressed directly to Nicola Booth at nicola.booth@adelphigroup.com. Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France; Pitié-Salpêtrière Hospital, AP-HP. Sorbonne Université, Rheumatology department, Paris, France; University of Utah Health and Salt Lake City Veterans Affairs Medical Center, Salt Lake City, UT, USA; University of Nebraska Medical Center, Omaha, NE, USA; Forward Databank, Wichita, KA, USA; Janssen Global Services, LLC, Horsham, PA, USA; Adelphi Real World, Bollington, UK; Janssen Research & Development, Spring House, PA, USA; Janssen Scientific Affairs, LLC, USA; Drexel University College of Medicine, Philadelphia, PA, USA; 11Perelman School of Medicine, Penn Medicine, Philadelphia, PA, USA. Conflicts of interest: LG: Research grants: Amgen, Galapagos, Janssen, Lilly, Pfizer, Sandoz, Sanofi; consulting fees: AbbVie, Amgen, BMS, Biogen, Celgene, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. JAW: Grants from AbbVie, Merck, Pfizer. Consulting for AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB, all unrelated to this work. KM: None disclosed. SP and CSK are employees and shareholders of Janssen Pharmaceuticals LLC. EAH and NB are employees of Adelphi Real World. SDC is an employee of Janssen Scientific Affairs, LLC and a shareholder in Johnson & Johnson, of which Janssen Scientific Affairs, LLC is a wholly-owned subsidiary. AO: Grant/research support from Amgen (to Forward), Novartis (to Penn) and Pfizer (to Penn) Inc. Consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Eli Lilly, Gilead, Janssen, Novartis, Pfizer Inc, and UCB. Address for correspondence: Pr. Laure Gossec Orcid ID: 0000-0002-4528-310X Hôpital Pitié-Salpétrière, Service de Rhumatologie, 47-83, boulevard de l'Hôpital - 75013 Paris, France laure.gossec@aphp.fr
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
Women with Psoriatic Arthritis Experience Higher Disease Burden than Men: Findings from a Real-World Survey in the USA and Europe
Laure Gossec, Jessica A. Walsh, Kaleb Michaud, Steve Peterson, Elizabeth A. Holdsworth, Chetan S. Karyekar, Nicola Booth, Soumya D. Chakravarty, Alexis Ogdie
The Journal of Rheumatology Aug 2022, jrheum.220154; DOI: 10.3899/jrheum.220154
Accepted manuscript
Women with Psoriatic Arthritis Experience Higher Disease Burden than Men: Findings from a Real-World Survey in the USA and Europe
Laure Gossec, Jessica A. Walsh, Kaleb Michaud, Steve Peterson, Elizabeth A. Holdsworth, Chetan S. Karyekar, Nicola Booth, Soumya D. Chakravarty, Alexis Ogdie
The Journal of Rheumatology Aug 2022, jrheum.220154; DOI: 10.3899/jrheum.220154